Details for New Drug Application (NDA): 021711
✉ Email this page to a colleague
The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.
Summary for 021711
Tradename: | ABLAVAR |
Applicant: | Lantheus Medcl |
Ingredient: | gadofosveset trisodium |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 2440MG/10ML (244MG/ML) | ||||
Approval Date: | Dec 22, 2008 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 3660MG/15ML (244MG/ML) | ||||
Approval Date: | Dec 22, 2008 | TE: | RLD: | No |
Expired US Patents for NDA 021711
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-001 | Dec 22, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription